Please login to the form below

Not currently logged in

Hospira’s oncology drug approved by FDA

Hospira gains approval from the FDA for new oncology drug, gemcitabine injection

The US Food and Drug Administration (FDA) has approved a new oncology drug by Hospira.

The approval was for gemcitabine injection, a solution form of the drug. The company says that this solution form reduces preparation time and gives the medical community “access to a lower-cost, more convenient offering” of the oncology drug. 

Hospira is hoping to launch the product by early September, and will be the first company to offer gemcitabine in a solution formulation for the US market. 

The concentration of the solution is the same as the reconstituted strength of the currently available “freeze-dried” form, but will eliminate the need for reconstitution, thus improving work flow, according to the company.

Hospira hopes that it will also improve pharmacist convenience and handling safety. 

8th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...